Exicure, Inc.
Records under this name other than the patents Exicure, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,837,018 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,182,988 | Liposomal Particles, Methods of Making Same and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,123,294 | Multivalent Delivery of Immune Modulators by Liposomal Spherical Nucleic Acids for Prophylactic or Therapeutic Applications Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,434,064 | Multivalent Delivery of Immune Modulators by Liposomal Spherical Nucleic Acids for Prophylactic or Therapeutic Applications Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,957,788 | Multivalent Delivery of Immune Modulators by Liposomal Spherical Nucleic Acids for Prophylactic or Therapeutic Applications Formerly held In force · Low confidence | In force | Low confidence | |
| US 10,208,310 | Anti-TNF compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,894,963 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,866,700 | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,696,954 | Synthesis of spherical nucleic acids using lipophilic moieties Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,760,080 | Anti-TNF compounds Formerly held Lapsed on the fee record Ended Sep 1, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 1, 2024 | From the USPTO record |